NCT00002267已完成不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Pharmacia74 个研究点 分布在 2 个国家目标入组 750 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 750
- 试验地点
- 74
研究概览
简要总结
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •Diagnosis of AIDS with a case defining infection other than Mycobacterium avium complex (MAC).
- •Written informed consent obtained, which must include a statement that treatment may involve risks to the embryo or fetus, which are currently unforeseeable, if the subject becomes pregnant.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine or didanosine (ddI).
- •Previous or current infection due to Mycobacterium avium complex (MAC) disease as evaluated by two successive blood cultures and two successive stool cultures taken within 14 days prior to study initiation.
- •Concurrent Medication:
- •Antiretroviral agents other than zidovudine (AZT).
- •Didanosine (ddI).
- •Antimycobacterial therapy.
- •Rifampin.
- •Isoniazid.
- •Clofazimine.
- •Ethambutol.
- •Cycloserine.
- •Ethionamide.
- •Amikacin.
- •Ciprofloxacin.
- •Streptomycin.
- •Other investigational drugs.
- •If antimicrobial therapy is required to treat bacterial infections (= or < 14 days), Adria Laboratories must be contacted prior to initiation of therapy.
- •Patients with the following are excluded:
- •Known hypersensitivity to rifabutin, rifampin, other rifamycins, zidovudine (AZT), or didanosine (ddI).
- •Previous or current Mycobacterium avium complex (MAC) infection.
- •Perceived patient unreliability or unavailability for frequent monitoring.
- •Prior Medication:
- •Excluded within 4 weeks of study entry:
- •Antiretroviral agents other than zidovudine (AZT) or didanosine (ddI).
- •Antimycobacterial therapy.
- •Rifampin.
- •Isoniazid.
- •Clofazimine.
- •Ethambutol.
- •Cycloserine.
- •Ethionamide.
- •Amikacin.
- •Ciprofloxacin.
- •Zidovudine (AZT).
- •Antipneumocystis prophylactic therapy.
- •Required for at least 4 weeks prior to study entry:
- •Zidovudine (AZT) or didanosine (ddI).
- •Antipneumocystis prophylaxis.
研究者
研究点 (74)
Loading locations...
相似试验
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002032Pharmacia750
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND StudyMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002080Pharmacia
已完成
不适用
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDSMycobacterium Avium-Intracellulare InfectionHIV InfectionsNCT00001995Pharmacia200
已完成
3 期
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment PatientsTuberculosisNCT00265226Ministry of Science and Technology, India1,020
已完成
2 期
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary SarcoidosisAntimycobacterial Therapy SarcoidosisNCT02024555Vanderbilt University97